ECSP23089582A - Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 - Google Patents

Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3

Info

Publication number
ECSP23089582A
ECSP23089582A ECSENADI202389582A ECDI202389582A ECSP23089582A EC SP23089582 A ECSP23089582 A EC SP23089582A EC SENADI202389582 A ECSENADI202389582 A EC SENADI202389582A EC DI202389582 A ECDI202389582 A EC DI202389582A EC SP23089582 A ECSP23089582 A EC SP23089582A
Authority
EC
Ecuador
Prior art keywords
potassium
channel blockers
agitator channel
spiroindolinone
compounds
Prior art date
Application number
ECSENADI202389582A
Other languages
English (en)
Inventor
Roger John Snow
Vishwanath Jogini
Morten Jensen
Fabrizio Giordanetto
Original Assignee
De Shaw Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Shaw Res Llc filed Critical De Shaw Res Llc
Publication of ECSP23089582A publication Critical patent/ECSP23089582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe un compuesto de la Fórmula I ( ) o una sal farmacéuticamente aceptable de este en donde los sustituyentes son como se definen en la presente descripción. También se describen composiciones farmacéuticas que comprenden el mismo y el método de uso del mismo.
ECSENADI202389582A 2021-05-28 2023-11-27 Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 ECSP23089582A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163194599P 2021-05-28 2021-05-28

Publications (1)

Publication Number Publication Date
ECSP23089582A true ECSP23089582A (es) 2023-12-29

Family

ID=84230386

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202389582A ECSP23089582A (es) 2021-05-28 2023-11-27 Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3

Country Status (19)

Country Link
US (1) US20240391926A1 (es)
EP (1) EP4351569A4 (es)
JP (1) JP7763271B2 (es)
KR (1) KR20240001192A (es)
CN (1) CN117597120A (es)
AR (1) AR125994A1 (es)
AU (1) AU2022281402A1 (es)
BR (1) BR112023023951A2 (es)
CA (1) CA3219345A1 (es)
CO (1) CO2023016088A2 (es)
CR (1) CR20230555A (es)
DO (1) DOP2023000257A (es)
EC (1) ECSP23089582A (es)
IL (1) IL308277A (es)
JO (1) JOP20230307A1 (es)
MX (1) MX2023013913A (es)
PH (1) PH12023553237A1 (es)
TW (1) TW202310831A (es)
WO (1) WO2022251561A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
TW202508566A (zh) * 2023-07-18 2025-03-01 丹麥商穆納醫療有限責任公司 Kv1.3鉀通道拮抗劑
AR133292A1 (es) * 2023-07-18 2025-09-17 Muna Therapeutics Aps Antagonistas del canal de potasio kv1.3
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor
WO2025235362A1 (en) * 2024-05-06 2025-11-13 D. E. Shaw Research, Llc INDOLINONE COMPOUNDS AS KCa3.1 POTASSIUM CHANNEL BLOCKERS
WO2025235367A1 (en) * 2024-05-06 2025-11-13 D. E. Shaw Research, Llc Azaindolinone compounds as kca3.1 potassium channel blockers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4345081A (en) * 1980-02-15 1982-08-17 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CN101108825A (zh) * 2003-04-04 2008-01-23 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
WO2014015495A1 (en) * 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3414247B1 (en) * 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
GB201811165D0 (en) * 2018-07-06 2018-08-29 Metrion Biosciences Ltd Novel compounds
CN110330498B (zh) * 2019-07-18 2022-03-08 麻王医药(深圳)有限公司 一种螺(3,3’-苯基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
CA3156980A1 (en) * 2019-10-07 2021-04-15 D. E. Shaw Research, Llc Aryl heterocyclic compounds as kv1.3 potassium shaker channel blockers
CR20220148A (es) * 2019-10-07 2022-07-03 De Shaw Res Llc Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3

Also Published As

Publication number Publication date
US20240391926A1 (en) 2024-11-28
BR112023023951A2 (pt) 2024-01-30
AU2022281402A1 (en) 2023-11-02
JOP20230307A1 (ar) 2023-11-27
EP4351569A2 (en) 2024-04-17
JP7763271B2 (ja) 2025-10-31
KR20240001192A (ko) 2024-01-03
CR20230555A (es) 2024-02-19
PH12023553237A1 (en) 2024-04-29
CA3219345A1 (en) 2022-12-01
AR125994A1 (es) 2023-08-30
WO2022251561A3 (en) 2023-01-05
WO2022251561A2 (en) 2022-12-01
MX2023013913A (es) 2024-02-12
DOP2023000257A (es) 2023-12-29
CN117597120A (zh) 2024-02-23
EP4351569A4 (en) 2025-04-16
TW202310831A (zh) 2023-03-16
CO2023016088A2 (es) 2024-02-26
JP2024522280A (ja) 2024-06-13
IL308277A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
ECSP23089582A (es) Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CO2022004305A2 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
MX2025009239A (es) Compuestos triciclicos para el tratamiento de cancer
PE20220134A1 (es) Compuestos de pirrolidina
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
MX2022004168A (es) Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3.
CR20230115A (es) Compuestos heterocíclicos
CR20220116A (es) Compuestos heterocíclicos
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
CL2023002616A1 (es) Inhibidores del sarcómero cardíaco
AR131282A1 (es) Compuestos novedosos
AR129946A1 (es) Inhibidores de cbl-b y métodos de uso de los mismos
MX2022004178A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
CO2024011857A2 (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1
AR134204A1 (es) Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos
CO2024005362A2 (es) Compuestos de cd73
DOP2023000209A (es) Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3
AR132377A1 (es) Compuestos novedosos
AR131472A1 (es) Moduladores de nampt
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
MX2023012958A (es) Compuestos y metodos anticonceptivos.
AR129212A1 (es) Compuestos piridona como inhibidores de trpa1